BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations

Abstract

One of the primary objectives of a dose-finding trial for novel anti-cancer agent combination therapies, such as molecular targeted agents and immune-oncology therapies, is to identify optimal dose combinations that are tolerable and therapeutically beneficial for subjects in subsequent clinical trials. The goal differs from that of a dose-finding trial for traditional cytotoxic agents, in which the goal is to determine the maximum tolerated dose combinations. This paper proposes the new design, named ‘BOIN-ETC’ design, to identify optimal dose combinations based on both efficacy and toxicity outcomes using the waterfall approach. The BOIN-ETC design is model-assisted, so it is expected to be robust, and straightforward to implement in actual oncology dose-finding trials. These characteristics are quite valuable from a practical perspective. Simulation studies show that the BOIN-ETC design has advantages compared with the other approaches in the percentage of correct optimal dose combination selection and the average number of patients allocated to the optimal dose combinations across various realistic settings.

Keywords

Bayesian adaptive dose-finding design drug combination efficacy-toxicity model-assisted design waterfall approach

Get full access to this article

View all access options for this article.

References

Druker

. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002; 1: 31–36.

Postel-Vinay

Arkenau

Ashley

. Clinical benefit in phase-I trials of novel molecularly targeted agents: does dose matter? Br J Cancer 2009; 100: 1373–1378.

Braun

. The bivariate continual reassessment method: extending the CRM to phase I trials of two competing outcomes. Control Clin Trials 2002; 23: 240–256.

Thall

Cook

. Dose-finding based on efficacy-toxicity trade-offs. Biometrics 2004; 60: 684–693.

Bekele

Shen

. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Biometrics 2005; 61: 344–354.

Riviere

Yuan

Dubois

, et al. A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent. J Roy Stat Soc Ser.C 2015; 64: 215–229.

Yuan

Nguyen

Thall

. Bayesian designs for phase I–II clinical trials. Chapman & Hall/CRC Biostatistics Series. New York: Chapman and Hall/ CRC Press, 2016.

Yan

Mandrekar

Yuan

. Keyboard: a novel Bayesian toxicity probability interval design for phase I clinical trials. Clin Cancer Res 2017; 23: 3994–4003.

Lin

Yin

. STEIN: a simple toxicity and efficacy interval design for seamless phase I/II clinical trials. Stat Med 2017; 36: 4106–4120.

10.

Whitmore

Guo

, et al. Toxicity and efficacy probability interval design for phase I adoptive cell therapy dose-finding clinical trials. Clin Cancer Res 2017; 23: 13–20.

11.

Takeda

Taguri

Morita

. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes. Pharm Stat 2018; 17: 383–395.

12.

Takeda

Morita

Taguri

. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes. Pharm Stat 2019; 19: 335–349.

13.

Lin

Zhou

Yan

, et al. BOIN12: Bayesian optimal interval phase I/II trial design for utility-based dose finding in immunotherapy and targeted therapies. JCO Precis Oncol 2020; 4: 1393–1402.

14.

Cai

Yuan

. A Bayesian dose finding design for oncology clinical trials of combinational biological agents. J Roy Stat Soc Ser C 2014; 63: 159–173.

15.

Guo

. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering. Stat Med 2015; 34: 859–875.

16.

Lyu

Zhao

, et al. AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose finding trials. J Roy Stat Soc Ser C 2019; 68: 385–410.

17.

Zhang

Yuan

. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials. Stat Med 2016; 35: 4924–4936.

18.

Liu

Yuan

. Bayesian optimal interval designs for phase I clinical trials. J Roy Stat Soc Ser.C 2015; 64: 507–523.

19.

Lin

Thall

Yuan

. An adaptive trial design to optimize dose-schedule regimes with delayed outcomes. Biometrics 2020; 76: 304–315.

20.

Zhou

Lee

Yuan

. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies. Stat Med 2019; 38: 5299–5316.

21.

Barlow

Bartholomew

Bremner

, et al. Statistical Inference under Order Restrictions. London: Wiley, 1972.

22.

Yamaguchi

Takeda

Yoshida

, et al. Optimal biological dose selection in dose-finding trials with model-assisted designs based on efficacy and toxicity: a simulation study. J Biopharm Stat 2023 Apr; 28: 1–15.

23.

Liu

Marin

Banerjee

, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. New England Journal of Medicine 2020; 382: 545–553.

24.

Takeda

Yamaguchi

Taguri

, et al. TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes. Biom J 2023; 65: e2200265.

25.

Zhou

Lin

Lee

, et al. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Stat Med 2022; 41: 1918–1931.

26.

Jin

Liu

Thall

, et al. Using data augmentation to facilitate conduct of phase I-II clinical trials with delayed outcomes. J Am Stat Assoc 2014; 109: 525–536.

27.

Yuan

, et al. gBOIN: a unified model-assisted phase I trial design accounting for toxicity grades, and binary or continuous end points. J Roy Stat Soc Ser.C 2018; 68: 289–308.

28.

Takeda

Xia

Liu

, et al. TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades. Pharm Stat 2022; 21: 496–506.

29.

Takeda

Morita

Taguri

. gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials. Biom J 2022; 64: 1178–1191.

30.

Zhou

Lee

Wang

Bailey

Yuan

. Incorporating historical information to improve phase I clinical trials. Pharm Stat 2021; 20(6): 1017–1034.

31.

Zhao

Liu

Takeda

. Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN-ET. Pharm Stat 2022. DOI: 10.1002/pst.2281.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.53 MB